[Influencing of side-effects of cytostatic drugs using metoclopramide].
D000577:Amides / Q000627:therapeutic use; D000840:Anisoles / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001565:Benzoates / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy; D005021:Ethylamines / Q000009:adverse effects / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D010078:Oxazines / Q000009:adverse effects / Q000627:therapeutic use; D017976:Phosphorus Acids / Q000009:adverse effects / Q000627:therapeutic use; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use; D014717:Vertigo / Q000139:chemically induced / Q000188:drug therapy; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000577:Amides; D000840:Anisoles; D000970:Antineoplastic Agents; D001565:Benzoates; D005021:Ethylamines; D010078:Oxazines; D017976:Phosphorus Acids; D011344:Procarbazine; D014747:Vinblastine
Beeinflussung von Zytostatika-Nebenwirkungen durch Metoclopramid.